Advertisement
News
Advertisement

Boston Scientific launches Synergy stent trial

Fri, 11/30/2012 - 9:56am
Mass Device

Boston Scientific says it's enrolled the 1st patient in the Evolve II clinical trial of its Synergy drug-eluting stent, in support of regulatory approvals in the U.S. and Japan.

Boston Scientific

Boston Scientific (NYSE:BSX) said the 1st patient was enrolled in the Evolve II clinical trial of its Synergy drug-eluting stent, aiming to use the data to back applications for approval in the U.S. and Japan.

The Natick, Mass.-based medical device company's everolimus-coated stent uses a bioabsorbable polymer designed to elute the drug for 3 months, leaving a bare platinum-chromium stent behind.

The 2,000-patient trial will follow its subjects for 5 years, according to a press release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading